|
Dr, Von Hoff is currently Physician in Chief, Senior Investigator and Director of Translational Research at the Translational Genomics Research Institute’s (TGen) Translational Drug Development Division and Head, Pancreatic Cancer Research Program in Phoenix, AZ. He also serves as Chief Scientific Officer for US Oncology and Scottsdale Clinical Research Institute. Dr. Von Hoff was involved in the early development of many cancer drugs, including paclitaxel, docetaxel, gemcitabine and others. Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in June 2004 March 2010. He is past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX Oncology, Inc. (recently acquired by Genzyme). He is founder and Editor Emeritus of Investigational New Drugs.The Journal of New Anticancer Agents; and Editor-in-Chief of Molecular Cancer Therapeutics. Dr. Von Hoff has published more than 531 papers, 129 book chapters, and more than 891 abstracts. | 